The Impact of Combining Cefepime or Ceftazidime with Steroidal and Anticoagulant Therapy in the Treatment of COVID-19 Patients

ABSTRACT

This study aimed to assess Cefepime or Ceftazidime efficacy when combined with steroid therapy (dexamethasone) and anticoagulant therapy (LMWH / Rivaroxaban) for COVID-19 patients. RT-PCR confirmed cases of Covid-19 in 367 (159 males) patients were treated with Cefepime or Ceftazidime, with steroids added to the treatment protocol. Patients were classified into two groups Group 1 mild and moderate cases (286 patients) and Group 2 serious cases (81 patients). Patients in Group 1 were divided into five sub-groups and the sixth is control group. Patients in Group 2 were divided into three subgroups. All patients were monitored daily, and we were able to determine how long they had to use the steroid, how long they had to be treated, and if oxygen treatment was required. The average of steroid period required for first 5 subgroups of Group 1 treatment was 4.01 days, while Group 2 required 9.17 days. The first 5 subgroups of Group 1 had a mean treatment period of 10 days, while Group 2 had 20.4 days. The patients in Group 2 required oxygen therapy for an average of 11.03 days, while the patients in Group 1 did not need oxygen therapy. The study's patients were all released alive. The steroidal duration needed and total treatment duration did not vary significantly between Group 1 subgroups. Ceftazidime or Cefepime is extremely successful in shortening the time of illness in Covid-19 patients. Their early use decreases the need for steroid therapy as well as oxygen therapy. In severe cases, combining Ivermectin, LMWH, and Rivaroxaban with Ceftazidime or Cefepime is advisable to shorten disease time, reduce thrombosis risk, and lower mortality risk. Cefepime showed better results in severe cases treatment than ceftazidime. Adding ivermectin showed a noticeable improvement. Copyright © 2022, Anka Publishers. All rights reserved.